Pablo Priego

Hidatidosis hepática: Cirugía radical vs. no radical: 22 años de experiencia

Objectives: the incidence of hepatic hydatidosis has remark ably decreased in the last years due to the preventive measures adopted to stop the transmission of the parasite. However, surgery carries on being the treatment of choice, although the surgical pro cedure is still a matter of controversy. The aim of the study was to evaluate the results obtained with the treatment of this condition after two decades according to surgical procedure type. Material and methods: from 1983 to 2005, 372 patients were operated on for hepatic hydatidic cyst in Hospital Ramon y Cajal. Radical surgery was performed for 162 (43.5%) and con servative surgery for 210 (56.5%). Results: average postoperative hospital stay (8.65 vs. 14.9 days), morbidity (13.3 vs. 31.4%, p < 0.001), and mortality (0 vs. 3.8%, p < 0.01) were lower in the radical surgery group. Recur rence rate was 1.85% after radical surgery versus 11.9% in the conservative surgery group (p < 0.0001). Conclusion: radical surgery is associated with lower morbidi ty, mortality, postoperative hospital stay, and recurrence rates, and represents the treatment of choice for hepatic hydatidosis. However, its indication must depend on the patient characteris tics, cyst anatomy, and surgical team experience.

Long-Term Results of Giant Hiatal Hernia Mesh Repair and Antireflux Laparoscopic Surgery for Gastroesophageal Reflux Disease

BACKGROUND The application of mesh-reinforced hiatal closure has resulted in a significant reduction in recurrence rates. The most debated issue is the risk of complications related to the use of the prosthesis, which are thought to be the cause of higher dysphagia. PATIENTS AND METHODS From January 2004 to December 2007, 198 consecutive patients underwent laparoscopic fundoplication for gastroesophageal reflux disease (GERD) with or without hiatal hernia. Fifty patients (25.3%) presented a giant hiatal hernia, defined as a hiatal defect over 5 cm. These 50 patients underwent primary simple suture of the crura and additional reinforcement with a Crurasoft mesh (Bard). Hiatal hernia or GERD symptoms recurrence, dysphagia, and mesh-related complications were investigated. RESULTS Of the 50 patients undergoing mesh repair, there were 32 women and 18 men with a mean age of 63.2 years. Conversion rate was 2%. Intraoperative complications rate was 6%, all of them laparoscopically managed. Postoperative complications occurred in 1 patient (2%). Mortality rate was 2%. Median postoperative stay was 3 days. Median follow-up was 62 months. Two percent of the patients presented wrap migration, and 4% presented dysphagia. Six percent of cases presented recurrence of GERD manifestations. There have been no complications related to the use of the mesh. CONCLUSIONS Laparoscopic antireflux surgery with a prosthetic mesh in cases of giant hiatal hernia is an effective and safe procedure, reducing the rate of postoperative hernia recurrence during long-term follow-up. The incidence of mesh-related complications is very low.

Portal Vein Thrombosis After Splenic and Pancreatic Surgery

The portal vein is formed by the confluence of the splenic and superior mesenteric veins, which drain the spleen and small intestine respectively. Occlusion of the portal vein by thrombus typically occurs in patients with cirrhosis and/or prothrombotic disorders. However, portal vein thrombosis (PVT) can also happen after determined surgeries. Moreover, PVT can have serious consequences depending on the location and extent of the thrombosis, including hepatic ischemia, intestinal ischemia, portal hypertension… In this chapter, we will review the incidence, management and prophylaxis of PVT after splenectomy, pancreas transplantation, pancreatic surgery and in the setting of acute and chronic pancreatitis.

Laparoscopic transgastric resection of gastric submucosal tumor located near the esophagogastric junction

Aim: Laparoscopic wedge resection is widely accepted as the choice of treatment for gastric submucosal tumors (GST). However, tumors on the posterior wall at the esophagogastric junction (EGJ) are difficult to approach. Laparoscopic transgastric resection (LTR) is a novel technique to remove gastric tumors that are unresectable by endoscopy due to their size and location. The aim of the article is to assess the feasibility and oncological outcomes of this laparoscopic approach for intraluminal GST located in the posterior wall and near the EGJ. Methods: A retrospective analysis of all patients with GST located at the EGJ who underwent LTR at our institution from January 2015 to February 2016 was performed. Results: Of the 4 patients who underwent LTR, 3 were female and 1 was male, with a mean age of 74.5 years. LTR was successfully performed in all the cases. All patients received a complete resection with negative margins. Histopathologic diagnoses were gastrointestinal stromal tumor in 2 cases and leiomyoma in the other 2. Median tumor size was 3.45 cm. The mean operation time was 173 min (range 120-232 min). One patient experienced a postoperative hematemesis, but was treated conservatively. The mean postoperative stay was 8 days (range 4-15 days). Conclusions: LTR is feasible and difficult localizations can be reached with ease. It is an appropriate alternative to laparoscopic wedge resections especially for localizations that cannot be accessed by laparoscopy such as tumors located near the EGJ.

Colitis por citomegalovirus sobre colitis isquémica en paciente inmunocompetente

Cytomegalovirus (CMV) colitis is a common entity in immunocompromised patients, being rare among immunocompetent individuals. In addition, its association with ischemic colitis is unusual in both groups of population. Rectal bleeding might occur in both entities and, occasionally, urgent surgical treatment may be required, associating high morbility rates. We report one case of cytomegalovirus colitis associated with severe ischemic colitis in a non- immunocompromised patient with favourable response to conservative management with antiviral therapy.